Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
27. Februar 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration ...
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
16. Mai 2023 06:00 ET
|
Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
Global Dystrophin Market to Reach USD 30.22 Billion by 2028 - Heavy Research & Development to Boost the Market Demand – Vantage Market Research
16. Februar 2022 05:35 ET
|
Vantage Market Research
WASHINGTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Global Dystrophin Market size is expected to reach USD 30.22 Billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 45.9% during the...
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
08. September 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
Prosensa Awarded $200,000 Research Grant from PPMD
27. Juni 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Holding N.V. to Webcast Conference Call Discussing 1st Quarter 2014 Financial Results and Corporate Update on May 20, 2014
13. Mai 2014 08:57 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, May 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Tuesday, May 20,...
Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne Muscular Dystrophy
21. Februar 2012 13:34 ET
|
CureDuchenne
Newport Beach, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a nonprofit organization that raises awareness and funds multiple research and development projects to cure Duchenne muscular...